(Q43248481)

17 November 2017

Effect of simvastatin vs. rosuvastatin on adiponectin and haemoglobin A1c levels in patients with non-ischaemic chronic heart failure (English)

1 reference

17 November 2017

1 reference

chronic heart failure

1 reference

Takayoshi Tsutamoto

1

1 reference

17 November 2017

Masayuki Yamaji

2

1 reference

17 November 2017

Chiho Kawahara

3

1 reference

17 November 2017

Keizo Nishiyama

4

1 reference

17 November 2017

Masanori Fujii

5

1 reference

17 November 2017

Takashi Yamamoto

6

1 reference

17 November 2017

Minoru Horie

7

1 reference

17 November 2017

language of work or name

1 reference

4 November 2009

1 reference

European Journal of Heart Failure

17 November 2017

1 reference

17 November 2017

11

1 reference

17 November 2017

12

1 reference

17 November 2017

1195-1201

1 reference

The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality

17 November 2017

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP144

The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP144

Diet-induced insulin resistance in mice lacking adiponectin/ACRP30

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP144

Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP144

Total and high molecular weight adiponectin, haemodynamics, and mortality in patients with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP144

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP144

Simvastatin improves flow-mediated dilation but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP144

Effect of atorvastatin versus rosuvastatin on levels of serum lipids, inflammatory markers and adiponectin in patients with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP144

Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP144

Disparity between angiographic regression and clinical event rates with hydrophobic statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP144

Insulin resistance in idiopathic dilated cardiomyopathy: a possible etiologic link

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP144

Relationship between tumor necrosis factor-alpha production and oxidative stress in the failing hearts of patients with dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP144

Prediction of mortality by high-sensitivity C-reactive protein and brain natriuretic peptide in patients with dilated cardiomyopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP144

Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP144

Simvastatin (40 mg/day), adiponectin levels, and insulin sensitivity in subjects with the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP144

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP144

Statins and newly diagnosed diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP144

Rosuvastatin increases vascular endothelial PPARgamma expression and corrects blood pressure variability in obese dyslipidaemic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP144

Effect of pravastatin and atorvastatin on glucose metabolism in nondiabetic patients with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP144

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP144

Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk--the PIOSTAT Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP144

Plasma oxidized low-density lipoprotein as a prognostic predictor in patients with chronic congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP144

Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP144

Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP144

Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP144

Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP144

Rosuvastatin in older patients with systolic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP144

Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP144

Insulin resistance in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP144

Insulin resistance and risk of congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP144

Insulin resistance is highly prevalent and is associated with reduced exercise tolerance in nondiabetic patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP144

Prognostic importance of insulin-mediated glucose uptake in aged patients with congestive heart failure secondary to mitral and/or aortic valve disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP144

The adipocyte-secreted protein Acrp30 enhances hepatic insulin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP144

21 January 2018

Identifiers

DOI

10.1093/EURJHF/HFP144

1 reference

17 November 2017

1 reference